MyMetabolon Login
© 2020 Metabolon, Inc. All rights reserved.
Metabolon Metabolon
  • Metabolomics
    • About Metabolomics
    • Our Process
    • Technology & Knowledgebase
    • Setting the Standard: The 4Cs
    • Our Latest Insights
  • Solutions
    • Column 1
      • Products & Services
        • Global Metabolomics
        • Lipidomics
        • Targeted Assays
        • Study Design & Consulting
        • Sample Preparation & Handling
        • Study Success Sample Handling Kit
        • Reporting & Interpretation
        • Bioinformatics
        • MyMetabolon Client Portal
    • Column 2
      • By Research & Development Phase
        • Discovery & Target Selection
        • Lead Candidate Selection
        • Preclinical
        • Clinical Development
        • Manufacturing & Bioprocessing
    • Column 3
      • By Therapeutic Area
        • Cardiovascular Disease
        • COVID-19
        • Diabetes
        • Gastrointestinal
        • Liver Disease
        • Microbiome
        • Neuroscience
        • Oncology
        • Renal & Urological Disorders
        • Respiratory Disorders
    • Column 4
      • By Sector
        • Academic
        • Agriculture
        • Biotech / Pharmaceutical
        • Precision Medicine
        • Nutrition
        • Personal Care & Cosmetics
        • Population Health
        • Veterinary & Animal Health
  • Insights
    • Our Latest Insights
    • Blog
    • News & Events
  • Resources
    • Resource Library
    • Client Stories
    • COVID-19
  • Company
    • About Us
    • Working With Us (FAQ)
    • Leadership
    • Careers
    • Strategic Partnering
    • News & Events
    • Contact Us
MyMetabolon
Demo Our Data
Metabolon
Demo Our Data

Metabolon, Inc. Joins SOPHIA, International Research Consortium

inCompany News

Group aims to improve risk assessment of complications of obesity and

predict treatment response for patients

MORRISVILLE, N.C. – August 6, 2020 – Metabolon, Inc., the global leader in metabolomics, has joined a new $20 million EU-supported international research consortium. SOPHIA (Stratification of Obese Phenotypes to Optimize Future Obesity Therapy), which includes 29 leading private and public research organizations in 12 countries, aims to improve risk assessment of complications of obesity and predict treatment response for people with obesity.

The World Health Organization estimates that obesity currently affects around 650 million people worldwide. There are about 200 known complications associated with obesity but predicting who will develop associated conditions or who will respond to obesity treatments is not yet understood. The SOPHIA consortium will identify, characterize and stratify clinically meaningful subpopulations of patients living with obesity to match the right treatment for the right person at the right time.

“While two individuals may have the same BMI, they will often respond differently to treatments like diet, drugs or surgery,” said Greg Michelotti, Ph.D., Scientific Director, Metabolon. “Our global approach to metabolomics will illuminate disease biomarkers, supporting proper stratification and therapeutic decisions to improve future outcomes for obese patients.”

Metabolon will perform metabolomics on 2,000 samples as part of the five-year longitudinal study to support greater understanding in patient stratification for the right treatment depending on metabolic profiles.

SOPHIA will provide evidence-based classification of predictors for obesity complications and response to obesity treatment while also identifying and charting models for sustainably developing treatment pathways that will be valuable for patients, healthcare systems, researchers and clinicians.

“Our mission within SOPHIA is to enable healthcare professionals to reliably predict the complications of obesity and who will respond to treatment,” said Prof. Carel le Roux, coordinator of SOPHIA and obesity physician at the Diabetes Complications Research Centre at University College Dublin.

SOPHIA Project Leader Dr Marianne Ølholm Larsen Grønning of Novo Nordisk, says: “Obesity is a complex, chronic disease and there is still a lot we do not know, both about the biology of the disease itself and how treatment can improve the lives of patients with obesity. SOPHIA is an important step towards understanding obesity better. The collaboration between academia, industry and associations promises strong and unique results.”

The voices of people living with obesity will be at the heart of SOPHIA through the establishment of a Patient Advisory Board. It will ensure that patients’ insights, opinions and wishes are placed at the core of SOPHIA and interwoven into the multiple layers of the study. The research group will use its findings to contribute to a more patient-centric and equitable narrative around obesity and its multiple impacts on individuals from both a social and medical perspective. It all starts with obesity being a chronic disease, not something people choose to live with.

SOPHIA will also investigate health outcomes in people with obesity who have type 1 diabetes. According to Dr Sanjoy Dutta, JDRF Vice President of Research, “With the statistical power afforded by such a large European collaboration, we will be able to investigate the two-way relationship between obesity and type 1 diabetes and ultimately be able to make valid predictions about health outcomes in this traditionally underappreciated population. Since recent epidemiological data indicate that nearly half of adults with T1D in some European countries have overweight or obesity, it is critical for the T1D community to address this challenge.”

The project officially kicked off its activities across Europe on June 1, 2020. The project will last until May 31, 2025, and the first milestone is already planned for September 2020.

The funding for this five-year project has been granted from the Innovative Medicines Initiative (IMI) – a joint undertaking of the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA); JDRF (formerly the Juvenile Diabetes Research Foundation); the Obesity Action Coalition; and T1D Exchange.

About IMI

The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI facilitates collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). For further information: www.imi.europa.eu

About Metabolomics

Metabolomics is the key to understanding biology, health, wellness and disease. All biological systems, including humans, are continually fueling a collection of chemical reactions. At its core, metabolomics is the large-scale study of small molecules, called metabolites, that comprise the metabolome. The science reveals the definitive representation of the phenotype of any biological system by measuring inputs from internal and external factors such as health, disease, nutrition, microbiome, medication, pollution, etc. As innovation in other life sciences areas has slowed, metabolomics is proving to be the next frontier in supporting companies in their understanding of data revealing state of health and the influences of genes, microbiome, diet, lifestyle and drug treatment on the state of health and progression of disease.

About Metabolon 
Metabolon, Inc., is the global leader in revealing new biological insights through metabolomics, harnessing the power of its Precision Metabolomics™ Platform to provide biological insights of disease state and physiological reactions in the present time. The company offers scalable, customizable metabolomics solutions from discovery through clinical trials and product life-cycle management. Leveraging one of the world’s most diverse and rich patient data sets, Metabolon is equipped to deliver biologically relevant insights to address some of the most difficult and pressing questions in the life sciences, helping to accelerate research and product development success in the biopharma, population health, consumer products, wellness and academic research sectors. For more information, please visit www.metabolon.com or follow us on LinkedIn or Twitter.

Media Inquiries:

Elizabeth Romero, Manager, Marketing Communications, Metabolon, Inc., Mobile: +1-954-461-7648, eromero@metabolon.com

Back to Events & Press
  • Metabolon Announces Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany
    Previous PostMetabolon Announces Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany
  • Next PostMetabolon and DNA Genotek: Collaborating to Advance Functional Understanding of the Microbiome
    Metabolon Announces Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany

Related Posts

Webinar: Unique advantages of incorporating untargeted and targeted metabolomics in drug development and clinical trials
Events

Webinar: Unique advantages of incorporating untargeted and targeted metabolomics in drug development and clinical trials

Leveraging Machine Learning to Advance Precision Medicine
Press

Leveraging Machine Learning to Advance Precision Medicine

National Institute of Allergy and Infectious Disease (NIAID) Selects Metabolon, Inc. for COVID-19 Study
Company News

National Institute of Allergy and Infectious Disease (NIAID) Selects Metabolon, Inc. for COVID-19 Study

Webinar: Deeper Understanding of COVID-19 Phenotypes Through Metabolomics: A Panel Discussion
Events

Webinar: Deeper Understanding of COVID-19 Phenotypes Through Metabolomics: A Panel Discussion

Metabolon’s Client Data Table enables study analysis
Blog Capabilities Working with Metabolon

Metabolon’s Client Data Table enables study analysis

Establishing industry QA/QC best practices for global metabolomics
Capabilities Working with Metabolon

Establishing industry QA/QC best practices for global metabolomics

Webinar: Mechanisms of Immune Control and Metabolomics
Events

Webinar: Mechanisms of Immune Control and Metabolomics

Metabolon, Inc. Announces $72 Million in Debt and Equity Financing to Accelerate Advancements in Precision Medicine and Innovative Drug Development Technologies
Company News

Metabolon, Inc. Announces $72 Million in Debt and Equity Financing to Accelerate Advancements in Precision Medicine and Innovative Drug Development Technologies

Event: BioProcess International
Events

Event: BioProcess International

Presentation: Leveraging Global Metabolomics at the Intersection of Physiology and Behavior (at MANA 2020)
Events

Presentation: Leveraging Global Metabolomics at the Intersection of Physiology and Behavior (at MANA 2020)

Metabolomics

  • About Metabolomics
  • Our Process
  • Technology & Knowledgebase
  • Setting the Standard: The 4Cs
  • Insights & Discoveries

Solutions

  • Products & Services
  • By Research & Development Phase
  • By Therapeutic Area
  • By Sector

Insights

  • Our Latest Insights
  • Blog
  • News & Events

Resources

  • Resource Library
  • Client Stories
  • COVID-19

Company

  • About Us
  • Working With Us (FAQ)
  • Leadership
  • Careers
  • Strategic Partnering
  • News & Events
  • Contact Us
Metabolon - Logo - Enlightening Life

Metabolon provides actionable biological insights to answer the toughest questions in life sciences research and drug development.

© 2021 Metabolon, Inc. All rights reserved. Privacy & Terms

in
Copy
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.